Linked Life Data

12324556

Source:http://linkedlifedata.com/resource/pubmed/id/12324556

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2002-9-26
pubmed:abstractText
Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis. A post hoc reanalysis by the Food and Drug Administration (FDA) of data from this study suggested that the reduction in mortality was restricted to patients with Acute Physiology and Chronic Health Evaluation (APACHE II) scores of 25 or more.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1533-4406
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Massachusetts Medical Society
pubmed:issnType
Electronic
pubmed:day
26
pubmed:volume
347
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
993-1000
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
An economic evaluation of activated protein C treatment for severe sepsis.
pubmed:affiliation
Department of Medicine, University of Calgary, Calgary, Alberta, Canada. braden.manns@calgaryhealthregion.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't